Enhertu Demonstrated Statistically Significant And Clinically Meaningful Improvement In Pfs

AZN•2026-08-17

Enhertu showed positive phase III results in lung cancer trial

AstraZeneca PLC said Enhertu® (fam-trastuzumab deruxtecan-nxki) demonstrated statistically significant and clinically meaningful improvement in progression-free survival (PFS) as a first-line treatment of patients with HER2-mutant advanced non-small cell lung cancer in the DESTINY-Lung04 phase III trial.

Enhertu Demonstrated Statistically Significant And Clinically Meaningful Improvement In Pfs

Enhertu showed positive phase III results in lung cancer trial

Related News

Alaska Air Group Inc cuts price objective to $60 from $65

Duke Energy outlines 2026 Carolinas resource plan prioritizing new gas generation, storage buildout

Why the energy shock hasn't been so bad for Europe this time

Prairie Operating amends Citibank-led credit agreement, eases current ratio covenant through 2026

Labcorp to host investor day webcast, outlines strategy and long-term outlook update